Benutzer: Gast  Login
Titel:

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Dokumenttyp:
Case Reports
Autor(en):
Huemer, Florian; Melchardt, Thomas; Jansko, Bettina; Wahida, Adam; Jilg, Stefanie; Jost, Philipp J; Klieser, Eckhard; Steiger, Katja; Magnes, Teresa; Pleyer, Lisa; Greil-Ressler, Sigrun; Rass, Christof; Greil, Richard; Egle, Alexander
Abstract:
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Between A...     »
Zeitschriftentitel:
Eur J Haematol
Jahr:
2019
Band / Volume:
102
Heft / Issue:
5
Seitenangaben Beitrag:
437-441
Sprache:
eng
Volltext / DOI:
doi:10.1111/ejh.13218
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/30725494
Print-ISSN:
0902-4441
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX